candesartan has been researched along with Dementia in 3 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess whether candesartan-based antihypertensive treatment in elderly patients with mildly to moderately elevated blood pressure confers a reduction in cardiovascular events, cognitive decline and dementia." | 5.10 | The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. ( Elmfeldt, D; Hansson, L; Hofman, A; Lithell, H; Olofsson, B; Skoog, I; Trenkwalder, P; Zanchetti, A, 2003) |
| "Arterial hypertension is closely correlated with the occurrence of stroke and also with the loss of cognitive function and dementia." | 2.42 | Neurological protection provided by candesartan: reviewing the latest study results. ( Leys, D, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lithell, H | 1 |
| Hansson, L | 1 |
| Skoog, I | 1 |
| Elmfeldt, D | 1 |
| Hofman, A | 1 |
| Olofsson, B | 1 |
| Trenkwalder, P | 1 |
| Zanchetti, A | 1 |
| Leys, D | 1 |
| Williams, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Hypertension Incidence and Diabetes Italian Assessment Study. Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects With Metabolic Syndrome and High-Normal Blood Pressure.[NCT00456963] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2007-09-30 | Terminated (stopped due to Because of delay in approval of the protocol by a number of Ethics Commitees the trial was terminated on March 4, 2010. No patient had received any study drug.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for candesartan and Dementia
| Article | Year |
|---|---|
Neurological protection provided by candesartan: reviewing the latest study results.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2003 |
Protection against stroke and dementia: an update on the latest clinical trial evidence.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl | 2004 |
1 trial available for candesartan and Dementia
| Article | Year |
|---|---|
The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Bl | 2003 |